Androgen receptor as prognostic marker in triple-negative breast cancer patients
Purpose: The purpose of this study was to assess the prognostic impact of androgen receptor (AR) expression in patients with triple-negative breast cancer (TNBC). Methods/patients: 101 patients treated for primary TNBC without distant metastasis from 1999 to 2015 were identified from breast surgery...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2018 |
| País: | España |
| Institución: | Universidad Complutense de Madrid (UCM) |
| Repositorio: | Docta Complutense |
| Idioma: | inglés |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/116473 |
| Acceso en línea: | https://hdl.handle.net/20.500.14352/116473 |
| Access Level: | acceso abierto |
| Palabra clave: | 616.1/.9 Androgen receptor Triple-negative breast cancer Prognosis Ciencias Biomédicas Medicina 32 Ciencias Médicas 3207 Patología |
| Sumario: | Purpose: The purpose of this study was to assess the prognostic impact of androgen receptor (AR) expression in patients with triple-negative breast cancer (TNBC). Methods/patients: 101 patients treated for primary TNBC without distant metastasis from 1999 to 2015 were identified from breast surgery database. Kaplan-Meier and Cox regression models evaluated disease-free survival (DFS) and overall survival (OS). Results: AR expression was positive (IHC>1%) in 40% of patients. OS at 36 and 60 months was 86% and 80% in AR-negative patients, and 100% and 96% in AR-positive patients (log rank test 0.036). DFS at 36 and 60 months was 78% and 68% in AR-negative and 92% and 89% in AR-positive (log rank test 0.075). Conclusions: Patients without AR expression have a significant correlation with poor outcome |
|---|